PerkinElmer to Present at J.P. Morgan Healthcare Conference

WALTHAM, Mass.–(BUSINESS WIRE)–Dec. 19, 2019– PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020 at 3:30 p.m. PT at the Westin St. Francis in San Francisco. Prahlad Singh, PerkinElmer’s president and... Read more

Danaher Announces Preliminary Results Of Envista Exchange Offer

WASHINGTON, Dec. 16, 2019 /PRNewswire/ — Danaher Corporation (NYSE: DHR) announced today the preliminary results of its previously announced offer to holders of shares of Danaher common stock to exchange their shares of Danaher common stock for shares of common stock of Envista Holdings Corporation (NYSE: NVST) owned by Danaher. The exchange offer expired at 12:00... Read more

PerkinElmer Launches First FDA-Approved Assay Kit to Screen for Duchenne Muscular Dystrophy in Newborns

Available on PerkinElmer’s automated GSP® instrument, kit supports early diagnosis by measuring CK-MM concentration instead of CK enzyme activity WALTHAM, Mass.–(BUSINESS WIRE)–Dec. 13, 2019– PerkinElmer, Inc., (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that its GSP® Neonatal Creatine Kinase –MM (CK-MM) kit has received U.S. Food & Drug... Read more

Bruker Completes Debt Financing to Support Corporate Strategic Objectives

BILLERICA, Mass., Dec. 12, 2019 /PRNewswire/ — Bruker Corporation (Nasdaq: BRKR) today announced that it has completed certain debt financing actions intended to enhance its financial flexibility and fund corporate strategic objectives. The actions include: (1) a new 5 year revolving credit facility with expanded capacity to borrow up to $600 million, (2) a new 7... Read more

Danaher Announces Final Exchange Ratio Of 5.5784 for Envista Exchange Offer

WASHINGTON, Dec. 11, 2019 /PRNewswire/ — Danaher Corporation (NYSE: DHR) announced today the final exchange ratio for its previously announced offer to holders of shares of Danaher common stock to exchange their shares of Danaher common stock for shares of common stock of Envista Holdings Corporation (NYSE: NVST) owned by Danaher. For each share of Danaher... Read more

PerkinElmer Announces Collaboration with Emerald Scientific for Cannabis and Hemp Analytical Solutions & Services

Both Companies to Exhibit at MJBizCon in Las Vegas this Week WHAT: PerkinElmer, Inc., a global leader committed to innovating for a healthier world, has announced a collaboration with Emerald Scientific, a leading cannabis and hemp lab technology provider and industry thought leader. With this agreement, Emerald Scientific will offer PerkinElmer’s cannabis and hemp testing portfolio... Read more

Bruker Introduces Dedicated Light-Sheet Microscope for Highly Multiplexed 3D Cell Culture Live Imaging

Luxendo TruLive3D Imager Enables Rapid Imaging of Cells and Organoids in Their Natural Environments WASHINGTON, Dec. 9, 2019 /PRNewswire/ — At the 2019 joint meeting of the American Society for Cell Biology (ASCB) and European Molecular Biology Organization (EMBO), Bruker (Nasdaq: BRKR) today announced the launch of the Luxendo TruLive3D Imager light-sheet imaging system. The new... Read more

Agilent Ranked Among Top Four Best Workplaces in Greater China And Receives Certification as a Best Workplace for Women in Greater China

Agilent Ranked Among Top Four Best Workplaces in Greater China and Receives Certification as a Best Workplace for Women in Greater China SANTA CLARA, Calif., December 6, 2019 Agilent Technologies, Inc. (NYSE: A) today announced it has been selected as one of the top four “Best Workplaces™ in Greater China” by the Great Place to... Read more

Thermo Fisher Scientific to Bring One-Day Genomic Profiling to Hematology Oncology

Thermo Fisher Scientific to Bring One-Day Genomic Profiling to Hematology Oncology Comprehensive myeloid assay available in 2020 to run on the Ion Torrent Genexus System CARLSBAD, Calif., Dec. 5, 2019 /PRNewswire/ — Clinical researchers who take a traditional sequential approach to analyze myeloid malignancies, a highly heterogeneous group of disorders, face a major hurdle: a... Read more